In summary, we demonstrated that CD45+EPCs take up soluble proteins, present antigenic epitopes on their surface, and induce antigen-specific CD8+ T-cell tolerance, thereby suppressing anti-tumor immunity. The gene discussed is PTPRC; the disease is neoplasm.